Avantax Advisory Services Inc. Takes Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Avantax Advisory Services Inc. bought a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) during the 4th quarter, HoldingsChannel.com reports. The fund bought 10,758 shares of the company’s stock, valued at approximately $127,000.

Several other institutional investors have also bought and sold shares of the stock. GAMMA Investing LLC grew its holdings in shares of Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after acquiring an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Roivant Sciences by 27.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock worth $84,000 after purchasing an additional 1,507 shares during the last quarter. Quarry LP grew its stake in Roivant Sciences by 50.0% in the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after purchasing an additional 2,500 shares during the period. Blue Trust Inc. increased its position in shares of Roivant Sciences by 550.1% during the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock valued at $91,000 after purchasing an additional 6,667 shares during the last quarter. Finally, HighTower Advisors LLC bought a new stake in shares of Roivant Sciences during the 4th quarter worth $121,000. Institutional investors own 64.76% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on ROIV shares. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Tuesday, February 11th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $17.10.

Roivant Sciences Stock Up 0.4 %

NASDAQ ROIV opened at $10.48 on Friday. The company has a market cap of $7.48 billion, a PE ratio of -69.86 and a beta of 1.26. Roivant Sciences Ltd. has a 52 week low of $9.96 and a 52 week high of $13.06. The firm’s 50-day simple moving average is $10.76 and its two-hundred day simple moving average is $11.43.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, equities research analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Insiders Place Their Bets

In other news, COO Eric Venker sold 434,478 shares of the firm’s stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $10.82, for a total value of $4,701,051.96. Following the completion of the transaction, the chief operating officer now directly owns 1,127,290 shares in the company, valued at approximately $12,197,277.80. This trade represents a 27.82 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Rakhi Kumar sold 227,500 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the sale, the chief accounting officer now directly owns 163,264 shares in the company, valued at $1,702,843.52. This trade represents a 58.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,573,245 shares of company stock worth $17,079,242 over the last 90 days. Corporate insiders own 7.90% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.